Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 13Recruiting 3Terminated 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 249Sarcoma 72Thoracic 10Gastrointestinal 10Breast 8Lymphoid 7Gynecologic 6Genitourinary 6Dermatologic 5Head & Neck 4Other hematologic neoplasm 3Classical hematology 3Plasma cell 2Other solid neoplasm 2Endocrine 2NET 1Myeloid 1

Conditions

Multiple Myeloma 477Neoplasms, Plasma Cell 102Lymphoma 86Lymphoma, Non-Hodgkin 75Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 71Recurrence 68Leukemia, Myeloid, Acute 68Leukemia 68Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Hodgkin Disease 66Lymphoma, Mantle-Cell 53Lymphoma, Large B-Cell, Diffuse 53Lymphoma, Follicular 45Myeloproliferative Disorders 43Neoplasms 41Lymphoma, B-Cell, Marginal Zone 41Burkitt Lymphoma 41Primary Myelofibrosis 38Lymphoma, Large-Cell, Immunoblastic 36Lymphoma, T-Cell, Cutaneous 31Leukemia, Myelomonocytic, Chronic 31Sezary Syndrome 29Mycosis Fungoides 29Leukemia, Myeloid, Chronic-Phase 29Leukemia, Myeloid, Accelerated Phase 29Congenital Abnormalities 29Leukemia, Hairy Cell 27Blast Crisis 27Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25

Interventions

ruxolitinib 1rucaparib 1ceritinib 1abiraterone 1Paclitaxel 1INCB057643 1Gemcitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Glioblastoma × Plasma cell × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡